$OPTN
OptiNose, Inc. Stock $optn

$optn Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000149465020000020 Filed on March 05, 2020

Income Statement

Concept	2020 Q1	2019 Q4	2019
Revenue	$7.062M	$11.08M	$34.63M
YoY Change	57.77%	266.89%	390.18%
Cost Of Revenue	$1.360M	$2.080M	$5.294M
YoY Change	84.28%	188.89%	233.38%
Gross Profit	$5.710M	$9.000M	$29.34M
YoY Change	52.76%	289.61%	435.64%
Gross Profit Margin	80.86%	81.23%	84.71%
Selling, General & Admin	$27.06M	$26.55M	$104.2M
YoY Change	2.73%	12.21%	8.93%
% of Gross Profit	473.91%	295.0%	355.03%
Research & Development	$4.932M	$5.380M	$20.78M
YoY Change	8.11%	60.12%	105.79%
% of Gross Profit	86.37%	59.78%	70.84%
Depreciation & Amortization	$309.0K	$230.0K	$1.108M
YoY Change	14.87%	9.52%	105.57%
% of Gross Profit	5.41%	2.56%	3.78%
Operating Expenses	$33.35M	$31.92M	$124.9M
YoY Change	5.4%	18.13%	18.18%
Operating Profit	-$26.29M	-$22.92M	-$95.60M
YoY Change	-3.23%	-7.24%	-4.63%
Interest Expense	$2.863M	-$2.070M	$9.623M
YoY Change	19.89%	22.49%	4.27%
% of Operating Profit
Other Income/Expense, Net		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Pretax Income	-$28.86M	-$25.00M	-$103.1M
YoY Change	-0.03%	-5.23%	-29.5%
Income Tax
% Of Pretax Income
Net Earnings	-$28.86M	-$25.00M	-$110.1M
YoY Change	-0.06%	-5.23%	3.18%
Net Earnings / Revenue	-408.61%	-225.63%	-317.79%
Basic Earnings Per Share
Diluted Earnings Per Share	-$628.6K	-$574.8K	-$2.628M
COMMON SHARES
Basic Shares Outstanding	45.91M shares	41.58M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$148.5M	$147.1M	$147.1M
YoY Change	-13.31%	-26.82%	-26.82%
Cash & Equivalents	$148.5M	$147.2M	$147.1M
Short-Term Investments
Other Short-Term Assets	$3.700M	$3.789M	$3.600M
YoY Change	-2.63%	73.57%	63.64%
Inventory	$5.709M	$3.484M	$3.500M
Prepaid Expenses
Receivables	$11.73M	$13.64M	$13.80M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$169.7M	$168.1M	$168.1M
YoY Change	-9.16%	-21.05%	-21.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.980M	$3.052M	$4.400M
YoY Change	-19.78%	-21.42%	12.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.513M	$1.538M	$200.0K
YoY Change	-39.36%	520.16%	0.0%
Total Long-Term Assets	$4.493M	$4.590M	$4.600M
YoY Change	-27.65%	11.08%	12.2%
TOTAL ASSETS
Total Short-Term Assets	$169.7M	$168.1M	$168.1M
Total Long-Term Assets	$4.493M	$4.590M	$4.600M
Total Assets	$174.2M	$172.7M	$172.7M
YoY Change	-9.75%	-20.43%	-20.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.403M	$3.625M	$3.600M
YoY Change	-29.61%	-49.06%	-49.3%
Accrued Expenses	$27.48M	$31.38M	$32.50M
YoY Change	55.39%	70.34%	76.63%
Deferred Revenue		$0.00
YoY Change		-100.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$34.23M	$36.14M	$36.10M
YoY Change	27.38%	40.64%	40.47%
LONG-TERM LIABILITIES
Long-Term Debt	$104.7M	$74.53M	$74.50M
YoY Change	44.02%	2.8%	2.76%
Other Long-Term Liabilities	$200.0K	$400.0K	$400.0K
YoY Change	-81.82%	100.0%	100.0%
Total Long-Term Liabilities	$104.9M	$74.53M	$74.90M
YoY Change	42.14%	2.8%	3.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$34.23M	$36.14M	$36.10M
Total Long-Term Liabilities	$104.9M	$74.53M	$74.90M
Total Liabilities	$139.0M	$111.1M	$111.1M
YoY Change	38.16%	12.9%	12.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$456.8M	-$428.0M
YoY Change	31.73%	34.62%
Common Stock	$492.0M	$489.6M
YoY Change	12.03%	12.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$35.13M	$61.58M	$61.60M
YoY Change
Total Liabilities & Shareholders Equity	$174.2M	$172.7M	$172.7M
YoY Change	-9.75%	-20.43%	-20.41%

Cashflow Statement

Concept	2020 Q1	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$28.86M	-$25.00M	-$110.1M
YoY Change	-0.06%	-5.23%	3.18%
Depreciation, Depletion And Amortization	$309.0K	$230.0K	$1.108M
YoY Change	14.87%	9.52%	105.57%
Cash From Operating Activities	-$27.97M	-$18.11M	-$90.82M
YoY Change	-5.81%	-10.35%	-1.09%
INVESTING ACTIVITIES
Capital Expenditures	$70.00K	-$70.00K	$557.0K
YoY Change	-58.33%	-70.83%	-67.04%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$70.00K	-$70.00K	-$557.0K
YoY Change	-58.33%	-70.83%	-67.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$77.60M
YoY Change
Debt Paid & Issued, Net			$80.18M
YoY Change
Cash From Financing Activities	$29.38M	39.83M	$37.53M
YoY Change	15526.6%	-49887.5%	-37.01%
NET CHANGE
Cash From Operating Activities	-$27.97M	-18.11M	-$90.82M
Cash From Investing Activities	-$70.00K	-70.00K	-$557.0K
Cash From Financing Activities	$29.38M	39.83M	$37.53M
Net Change In Cash	$1.335M	21.65M	-$53.85M
YoY Change	-104.5%	-205.51%	59.01%
FREE CASH FLOW
Cash From Operating Activities	-$27.97M	-$18.11M	-$90.82M
Capital Expenditures	$70.00K	-$70.00K	$557.0K
Free Cash Flow	-$28.04M	-$18.04M	-$91.37M
YoY Change	-6.11%	-9.62%	-2.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001494650
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	001-38241
CY2019	dei	Entity Registrant Name EntityRegistrantName	OPTINOSE, INC.
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	Yardley
CY2019	dei	City Area Code CityAreaCode	267
CY2019	dei	Local Phone Number LocalPhoneNumber	364-3500
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	42-1771610
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	1020 Stony Hill Road
CY2019	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19067
CY2019	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2019	dei	Trading Symbol TradingSymbol	OPTN
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019Q2	dei	Entity Public Float EntityPublicFloat	174100000	USD
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45906162	shares
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	147144000	USD
CY2018Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	200990000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3625000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13643000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2310000	USD
CY2019Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	175000	USD
CY2018Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	242000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	3484000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	7132000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3614000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2183000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	168060000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	212857000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3052000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3884000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1538000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	248000	USD
CY2019Q4	us-gaap	Assets Assets	172650000	USD
CY2018Q4	us-gaap	Assets Assets	216989000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7116000	USD
CY2019Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	32514000	USD
CY2018Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	18421000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	160000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36139000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25697000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	74531000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	72500000	USD
CY2019Q4	us-gaap	Other Liabilities OtherLiabilities	397000	USD
CY2018Q4	us-gaap	Other Liabilities OtherLiabilities	181000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	111067000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	98378000	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45906162	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45906162	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41227530	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41227530	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	46000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	41000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	489565000	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	436554000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-427980000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-317927000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-57000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	61583000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	118611000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	172650000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	216989000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34631000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7065000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5294000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1588000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20783000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10099000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	104155000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	95618000	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	130232000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	107305000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-95601000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-100240000	USD
CY2019	optn	Grantand Other Income GrantandOtherIncome	0	USD
CY2018	optn	Grantand Other Income GrantandOtherIncome	406000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	2359000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	2453000	USD
CY2019	us-gaap	Interest Expense InterestExpense	9623000	USD
CY2018	us-gaap	Interest Expense InterestExpense	9229000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-33000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-48000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7155000	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-110053000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-106658000	USD
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.63
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.68
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	41877527	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39765983	shares
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-110053000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-106658000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	9000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	54000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-110044000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-106604000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	154496000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8645000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	59917000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1418000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	739000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	54000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-106658000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	118611000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9999000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	38747000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1038000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	1008000	USD
CY2019	optn	Stock Issued During Period Value Warrants Issued StockIssuedDuringPeriodValueWarrantsIssued	2224000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	9000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-110053000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	61583000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-110053000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-106658000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1108000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	539000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	9860000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	8543000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	658000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	404000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7155000	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11333000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2310000	USD
CY2019	optn	Increase Decrease In Grantsand Other Receivables IncreaseDecreaseInGrantsandOtherReceivables	-68000	USD
CY2018	optn	Increase Decrease In Grantsand Other Receivables IncreaseDecreaseInGrantsandOtherReceivables	196000	USD
CY2019	optn	Increase Decreasein Depositsand Other Assets IncreaseDecreaseinDepositsandOtherAssets	26000	USD
CY2018	optn	Increase Decreasein Depositsand Other Assets IncreaseDecreaseinDepositsandOtherAssets	762000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3759000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4698000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3856000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3171000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	11845000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	10150000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-90815000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-91817000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	557000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1690000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-557000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1690000	USD
CY2019	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	41438000	USD
CY2018	us-gaap	Proceeds From Issuance Of Redeemable Preferred Stock ProceedsFromIssuanceOfRedeemablePreferredStock	63969000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	77596000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	optn	Proceedsfrom Issuanceof Common Stock Under Employee Stock Purchase Plan ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan	2404000	USD
CY2018	optn	Proceedsfrom Issuanceof Common Stock Under Employee Stock Purchase Plan ProceedsfromIssuanceofCommonStockUnderEmployeeStockPurchasePlan	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1008000	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	739000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1038000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1488000	USD
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	5776000	USD
CY2018	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	6547000	USD
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	70000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	80179000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	37529000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	59579000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-53846000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-33864000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201011000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	234875000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147165000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	201011000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	8785000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	8253000	USD
CY2019	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	38000	USD
CY2018	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	146000	USD
CY2019	optn	Noncash Fixed Assets Acquired Through Tenant Allowance NoncashFixedAssetsAcquiredThroughTenantAllowance	0	USD
CY2018	optn	Noncash Fixed Assets Acquired Through Tenant Allowance NoncashFixedAssetsAcquiredThroughTenantAllowance	361000	USD
CY2019	optn	Deferred Offering Costs W Ithin Accounts Payableand Accrued Expenses DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses	483000	USD
CY2018	optn	Deferred Offering Costs W Ithin Accounts Payableand Accrued Expenses DeferredOfferingCostsWIthinAccountsPayableandAccruedExpenses	0	USD
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	2483000	USD
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2959000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2019	us-gaap	Nature Of Operations NatureOfOperations	Organization and Description of Business<div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">OptiNose, Inc. (the Company) was incorporated in Delaware in May 2010 (inception) and has facilities in Yardley, Pennsylvania, Ewing, New Jersey, Oslo, Norway and Swindon, England. The Company's predecessor entity, OptiNose AS, was formed under the laws of Norway in September 2000. In 2010, OptiNose AS became a wholly-owned subsidiary of the Company as part of an internal reorganization.</span></div><div style="margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. The Company's first commercial product, XHANCE</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">®</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (fluticasone propionate) nasal spray, 93 mcg, is a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). XHANCE was approved by the United States (US) Food and Drug Administration (FDA) in September 2017 for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018.</span></div>
CY2019Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	147144000	USD
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of estimates</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</span></div>
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of credit risk</span></div><div style="margin-top:8pt;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and accounts receivable.The Company generally invests its cash in deposits with high credit quality financial institutions. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.</span></div>
CY2019Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	145634000	USD
CY2018Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	199507000	USD
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	18528000	USD
CY2018	us-gaap	Advertising Expense AdvertisingExpense	9767000	USD
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10076405	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8081596	shares
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1227000	USD
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1969000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	676000	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2344000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1581000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2819000	USD
CY2019Q4	us-gaap	Inventory Gross InventoryGross	3484000	USD
CY2018Q4	us-gaap	Inventory Gross InventoryGross	7132000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5299000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5035000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2247000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1151000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3052000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3884000	USD
CY2019	us-gaap	Depreciation Depreciation	1106000	USD
CY2018	us-gaap	Depreciation Depreciation	535000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2411000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2887000	USD
CY2019	optn	Lessee Lease Renewal Term LesseeLeaseRenewalTerm	P3Y
CY2019Q4	optn	Operating Lease Right Of Use Asset Noncurrent OperatingLeaseRightOfUseAssetNoncurrent	1386000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1135000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	397000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1532000	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M26D
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1193000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	401000	USD
CY2019Q4	optn	Lessee Operating Lease Liability Payments Due Thereafter LesseeOperatingLeaseLiabilityPaymentsDueThereafter	0	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1594000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	62000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1532000	USD
CY2019	optn	Operating Lease Cost For Extension OperatingLeaseCostForExtension	44000	USD
CY2019	us-gaap	Lease Cost LeaseCost	2154000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	1589000	USD
CY2019Q4	optn	Accrued Sales Organization Expenses Current AccruedSalesOrganizationExpensesCurrent	12858000	USD
CY2018Q4	optn	Accrued Sales Organization Expenses Current AccruedSalesOrganizationExpensesCurrent	2856000	USD
CY2019Q4	optn	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	5544000	USD
CY2018Q4	optn	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	4812000	USD
CY2019Q4	optn	Accrued Selling Generaland Administrative Current AccruedSellingGeneralandAdministrativeCurrent	3379000	USD
CY2018Q4	optn	Accrued Selling Generaland Administrative Current AccruedSellingGeneralandAdministrativeCurrent	933000	USD
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	7810000	USD
CY2018Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	4199000	USD
CY2019Q4	optn	Accrued Product Allowances Current AccruedProductAllowancesCurrent	0	USD
CY2018Q4	optn	Accrued Product Allowances Current AccruedProductAllowancesCurrent	4482000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1788000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1139000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	31379000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	18421000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1135000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1135000	USD
CY2019Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	32514000	USD
CY2018Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	18421000	USD
CY2019	us-gaap	Proceeds From License Fees Received ProceedsFromLicenseFeesReceived	70000000	USD
CY2019	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1238000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	645000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	178000	USD
CY2019Q4	us-gaap	Purchase Obligation PurchaseObligation	0	USD
CY2019Q4	optn	Vote Per Share VotePerShare	1	vote
CY2019	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9860000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8543000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-103109000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-146247000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-6944000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	39589000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-110053000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-106658000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.008
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.005
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.008
CY2019	optn	Effective Income Tax Rate Reconciliation Foreign Operations Impact Percent EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent	0
CY2018	optn	Effective Income Tax Rate Reconciliation Foreign Operations Impact Percent EffectiveIncomeTaxRateReconciliationForeignOperationsImpactPercent	-0.072
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.030
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.039
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.006
CY2019	optn	Effective Income Tax Rate Reconciliation Foreign Exchange Other Percent EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent	0.007
CY2018	optn	Effective Income Tax Rate Reconciliation Foreign Exchange Other Percent EffectiveIncomeTaxRateReconciliationForeignExchangeOtherPercent	-0.006
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.239
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.162
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	4349000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	1674000	USD
CY2019Q4	optn	Deferred Tax Assets Prepaid License Arrangement DeferredTaxAssetsPrepaidLicenseArrangement	11154000	USD
CY2018Q4	optn	Deferred Tax Assets Prepaid License Arrangement DeferredTaxAssetsPrepaidLicenseArrangement	11562000	USD
CY2019Q4	optn	Deferred Tax Assets Interest Expense DeferredTaxAssetsInterestExpense	4469000	USD
CY2018Q4	optn	Deferred Tax Assets Interest Expense DeferredTaxAssetsInterestExpense	1267000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	5468000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	3493000	USD
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2485000	USD
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2485000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	51644000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	32548000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	79569000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	53029000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	630000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	409000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	630000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	409000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	78939000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52620000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	26319000	USD

Files In Submission

Name	View Source	Status
0001494650-20-000020-index-headers.html	Edgar Link	pending
0001494650-20-000020-index.html	Edgar Link	pending
0001494650-20-000020.txt	Edgar Link	pending
0001494650-20-000020-xbrl.zip	Edgar Link	pending
auditorconsent10-kex231.htm	Edgar Link	pending
descriptionofsecuritie.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
formindemnificationagr.htm	Edgar Link	pending
listofsubsidiariesex211.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
optn-20191231.htm	Edgar Link	pending
optn-20191231.xsd	Edgar Link	pending
optn-20191231_cal.xml	Edgar Link	unprocessable
optn-20191231_def.xml	Edgar Link	unprocessable
optn-20191231_g1.jpg	Edgar Link	pending
optn-20191231_g2.jpg	Edgar Link	pending
optn-20191231_g3.jpg	Edgar Link	pending
optn-20191231_g4.jpg	Edgar Link	pending
optn-20191231_g5.jpg	Edgar Link	pending
optn-20191231_g6.jpg	Edgar Link	pending
optn-20191231_g7.jpg	Edgar Link	pending
optn-20191231_htm.xml	Edgar Link	completed
optn-20191231_lab.xml	Edgar Link	unprocessable
optn-20191231_pre.xml	Edgar Link	unprocessable
optn12-31x201910xkex311.htm	Edgar Link	pending
optn12-31x201910xkex312.htm	Edgar Link	pending
optn12-31x201910xkex32.htm	Edgar Link	pending
optn12-31x201910xkex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPTN
OptiNose, Inc. Stock $optn

2020 Q1 Form 10-K Financial Statement

#000149465020000020 Filed on March 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPTN OptiNose, Inc. Stock $optn

2020 Q1 Form 10-K Financial Statement

#000149465020000020 Filed on March 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPTN
OptiNose, Inc. Stock $optn